Salarius Pharmaceuticals Invested 2018

Salarius Pharmaceuticals successfully completed a reverse merger with Flex Pharma in August 2019, creating a quick liquidity event for VisionTech Angels investors. Salarius, which now trades on Nasdaq under SLRX, returned common stock to investors less than 10 months after their original investment. Salarius is an emerging biotechnology company developing targeted therapies to treat rare pediatric and other cancers, including advanced solid tumors. The company’s lead compound Seclidemstat represents a potential paradigm shift in the treatment of cancer with an initial target of Ewing sarcoma, a devastating pediatric, adolescent and young adult bone cancer where no targeted therapies are currently available.


Looking for Funding?

VisionTech Partners may be able to help. Through VisionTech Angels and a broad network of investors and business resources, our goal is to help promising ventures succeed. We focus on early stage and early growth technology-based companies in Indiana and the Midwest.

If you have questions or would like more information, Contact Us. If you’re ready to start the process, Submit Your Business Plan using the secure website of Gust, the global platform for angel investing. We look forward to hearing from you!